STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Danaher Corporation Stock Price, News & Analysis

DHR NYSE

Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.

Danaher Corporation (NYSE: DHR) drives innovation in life sciences, diagnostics, and industrial technologies through cutting-edge scientific instruments and operational excellence. This page serves as a centralized hub for all official company announcements, press releases, and market-moving developments.

Investors and industry professionals will find timely updates on earnings reports, strategic acquisitions, and product innovations that shape Danaher's leadership across healthcare and industrial markets. Our curated news collection simplifies tracking regulatory filings, partnership announcements, and operational milestones.

Key content categories include quarterly financial results, R&D breakthroughs in diagnostic systems, and updates from Danaher's core segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Bookmark this page to stay informed about developments impacting the company's position in precision medicine and industrial automation.

Rhea-AI Summary

Danaher Corporation (NYSE: DHR) reported strong financial results for Q4 and full year 2020. Q4 net earnings reached $1.2 billion ($1.66 per share), up 55% year-over-year, while revenues climbed 39% to $6.8 billion. Full year net earnings totaled $3.6 billion ($4.89 per share), reflecting a 50% increase, with total revenues at $22.3 billion, a 24.5% rise. The company anticipates mid to high-teens non-GAAP core revenue growth for Q1 2021 and low-double digits for the full year. The acquisition of Cytiva significantly bolstered Danaher's market position and long-term value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.87%
Tags
-
Rhea-AI Summary

Beckman Coulter announced the launch of the DxH 560 AL, a compact tabletop analyzer designed for small to mid-sized laboratories. This innovative device features Auto-Loading functionality, allowing for continuous sample addition of up to 50, while minimizing manual tasks and resource usage. It requires only 17 μL of blood, making it ideal for difficult-to-draw patients, and delivers results in under 60 seconds. The DxH 560 AL aims to provide large laboratory efficiency at a lower cost, enhancing productivity without exceeding budgetary constraints.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
-
Rhea-AI Summary

Beckman Coulter announced the launch of the DxH 560 AL, a tabletop analyzer designed for small to mid-sized laboratories. This innovative device features auto-loading functionality, accommodating up to 50 samples and requiring only a 17 μL sample volume, among the lowest in the market. The DxH 560 AL provides results in under 60 seconds, enhancing efficiency. It also includes advanced security features for patient data protection. The analyzer is part of the DxH 500 series, offering high-throughput capabilities while remaining budget-friendly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
Rhea-AI Summary

On January 13, 2021, Danaher Corporation (NYSE: DHR) announced strong financial performance for Q4 2020 during the J.P. Morgan Healthcare Conference. The company expects core revenue growth, including Cytiva, to exceed previous guidance, driven by robust results in Life Sciences and Diagnostics segments. Estimated revenues rose approximately 38.5% year-over-year, with non-GAAP core revenue growth estimated at 15%. Danaher will report full earnings on January 28, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
none
-
Rhea-AI Summary

Danaher Corporation (NYSE: DHR) will have its President and CEO, Rainer M. Blair, present at the J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET. This presentation will be available via a live audio webcast and will be archived for later access on Danaher’s website.

As a leader in science and technology, Danaher focuses on solving complex challenges across healthcare and environmental markets, employing over 67,000 associates committed to improving quality of life globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
conferences
-
Rhea-AI Summary

Danaher Corporation (NYSE: DHR) has announced its upcoming quarterly earnings conference call for the fourth quarter of 2020, scheduled for January 28, 2021, at 8:00 a.m. ET. The call will last approximately one hour and will be available via webcast on Danaher's website. A replay will be accessible after the call until February 11, 2021. Additional related materials will be posted on the website at 6:00 a.m. ET on the call date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
conferences earnings
News
Rhea-AI Summary

Danaher Corporation (NYSE: DHR) announced the appointment of Dr. Jose-Carlos Gutierrez-Ramos as Senior Vice President and Chief Scientific Officer. Reporting directly to President and CEO Rainer M. Blair, Gutierrez-Ramos will lead Danaher’s science and technology strategy. A seasoned expert, he joins from Abbvie, where he was Head of Global Drug Discovery. His previous roles include leadership positions at Repertoire Immune Medicines and Pfizer, among others. Gutierrez-Ramos holds a Ph.D. in Immunology and extensive experience in academia and R&D.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
News
Rhea-AI Summary

Danaher Corporation (NYSE: DHR) appointed Jennifer L. Honeycutt as Executive Vice President, effective January 1, 2021. Honeycutt will oversee Beckman Coulter Life Sciences, Integrated DNA Technologies, and other key businesses. Previously, she served as Vice President and Group Executive for Pall and IDT in China, and President of Pall and Beckman Coulter. Her leadership is noted for driving growth within the Life Sciences platform. With 20 years at Danaher, she holds degrees in Chemistry and French, along with an MBA in Technology Management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
News
Rhea-AI Summary

Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.18 per share for common stock, scheduled for payment on January 29, 2021 to shareholders of record as of December 28, 2020. Additionally, a dividend of $11.875 per share will be paid for its 4.75% Series A Mandatory Convertible Preferred Stock and $12.50 for the 5.00% Series B Mandatory Convertible Preferred Stock, both payable on January 15, 2021 to holders of record on December 31, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
dividends
Rhea-AI Summary

Danaher Corporation (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the Evercore ISI HealthCONx Conference on December 1, 2020, at 8:50 a.m. ET. The presentation will be available via audio webcast on www.danaher.com. Danaher is a global science and technology innovator focused on solving complex challenges in health care, environmental, and applied markets. The company operates over 20 businesses and employs more than 67,000 associates, united by the Danaher Business System and a mission to enhance quality of life worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences

FAQ

What is the current stock price of Danaher Corporation (DHR)?

The current stock price of Danaher Corporation (DHR) is $228.46 as of December 3, 2025.

What is the market cap of Danaher Corporation (DHR)?

The market cap of Danaher Corporation (DHR) is approximately 160.1B.
Danaher Corporation

NYSE:DHR

DHR Rankings

DHR Stock Data

160.05B
629.04M
11.05%
82.81%
1.33%
Diagnostics & Research
Industrial Instruments for Measurement, Display, and Control
Link
United States
WASHINGTON